

Peter Man-Un Ung

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5673871/publications.pdf>

Version: 2024-02-01

34
papers

1,704
citations

331670

21
h-index

377865

34
g-index

35
all docs

35
docs citations

35
times ranked

2879
citing authors

#	ARTICLE	IF	CITATIONS
1	Automated genome mining for natural products. <i>BMC Bioinformatics</i> , 2009, 10, 185.	2.6	219
2	SLC transporters: structure, function, and drug discovery. <i>MedChemComm</i> , 2016, 7, 1069-1081.	3.4	152
3	Binding of a Small Molecule at a Protein-Protein Interface Regulates the Chaperone Activity of Hsp70-Hsp40. <i>ACS Chemical Biology</i> , 2010, 5, 611-622.	3.4	149
4	CSAR Benchmark Exercise of 2010: Selection of the Protein-Ligand Complexes. <i>Journal of Chemical Information and Modeling</i> , 2011, 51, 2036-2046.	5.4	133
5	CSAR Benchmark Exercise of 2010: Combined Evaluation Across All Submitted Scoring Functions. <i>Journal of Chemical Information and Modeling</i> , 2011, 51, 2115-2131.	5.4	133
6	Molecular Basis for Redox Activation of Epidermal Growth Factor Receptor Kinase. <i>Cell Chemical Biology</i> , 2016, 23, 837-848.	5.2	100
7	Chemical Screens against a Reconstituted Multiprotein Complex: Myricetin Blocks DnaJ Regulation of DnaK through an Allosteric Mechanism. <i>Chemistry and Biology</i> , 2011, 18, 210-221.	6.0	94
8	Redefining the Protein Kinase Conformational Space with Machine Learning. <i>Cell Chemical Biology</i> , 2018, 25, 916-924.e2.	5.2	65
9	Mutagenesis Reveals the Complex Relationships between ATPase Rate and the Chaperone Activities of Escherichia coli Heat Shock Protein 70 (Hsp70/DnaK). <i>Journal of Biological Chemistry</i> , 2010, 285, 21282-21291.	3.4	62
10	A whole-animal platform to advance a clinical kinase inhibitor into new disease space. <i>Nature Chemical Biology</i> , 2018, 14, 291-298.	8.0	56
11	Inhibitor Discovery for the Human GLUT1 from Homology Modeling and Virtual Screening. <i>ACS Chemical Biology</i> , 2016, 11, 1908-1916.	3.4	49
12	Identifying binding hot spots on protein surfaces by mixed-solvent molecular dynamics: HIV-1 protease as a test case. <i>Biopolymers</i> , 2016, 105, 21-34.	2.4	40
13	A poke in the eye: Inhibiting HIV-1 protease through its flap-recognition pocket. <i>Biopolymers</i> , 2008, 89, 643-652.	2.4	39
14	An IRAK1-PIN1 signalling axis drives intrinsic tumour resistance to radiation therapy. <i>Nature Cell Biology</i> , 2019, 21, 203-213.	10.3	38
15	DFGmodel: Predicting Protein Kinase Structures in Inactive States for Structure-Based Discovery of Type-II Inhibitors. <i>ACS Chemical Biology</i> , 2015, 10, 269-278.	3.4	37
16	Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β^2 -cell proliferation activity. <i>European Journal of Medicinal Chemistry</i> , 2018, 157, 1005-1016.	5.5	36
17	Chemical Probes That Selectively Recognize the Earliest $A\beta^2$ Oligomers in Complex Mixtures. <i>Journal of the American Chemical Society</i> , 2010, 132, 17655-17657.	13.7	33
18	Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling. <i>Cancer Discovery</i> , 2021, 11, 1716-1735.	9.4	30

#	ARTICLE	IF	CITATIONS
19	KinaMetrix: a web resource to investigate kinase conformations and inhibitor space. <i>Nucleic Acids Research</i> , 2019, 47, D361-D366.	14.5	28
20	Structures of ligand-occupied Î²-Klotho complexes reveal a molecular mechanism underlying endocrine FGF specificity and activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 7819-7824.	7.1	27
21	High-Resolution Structure and Inhibition of the Schizophrenia-Linked Pseudokinase ULK4. <i>Journal of the American Chemical Society</i> , 2020, 142, 33-37.	13.7	24
22	An Allosteric Modulator of HIV-1 Protease Shows Equipotent Inhibition of Wild-Type and Drug-Resistant Proteases. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 6468-6478.	6.4	23
23	Identification of Key Hinge Residues Important for Nucleotide-Dependent Allostery in <i>E. coli</i> Hsp70/DnaK. <i>PLoS Computational Biology</i> , 2013, 9, e1003279.	3.2	20
24	Identification of a G-Protein-Independent Activator of GIRK Channels. <i>Cell Reports</i> , 2020, 31, 107770.	6.4	20
25	GEN3VA: aggregation and analysis of gene expression signatures from related studies. <i>BMC Bioinformatics</i> , 2016, 17, 461.	2.6	17
26	E230Q mutation of the catalytic subunit of cAMP-dependent protein kinase affects local structure and the binding of peptide inhibitor. <i>Biopolymers</i> , 2006, 81, 428-439.	2.4	15
27	Encounter and React: Computer-Guided Design of Covalent Inhibitors. <i>Cell Chemical Biology</i> , 2019, 26, 6-8.	5.2	14
28	Functional and structural analysis of rare SLC2A2 variants associated with Fanconi-Bickel syndrome and metabolic traits. <i>Human Mutation</i> , 2019, 40, 983-995.	2.5	13
29	Role of the CCAAT/Enhancer-binding Protein NFATc2 Transcription Factor Cascade in the Induction of Secretory Phospholipase A2. <i>Journal of Biological Chemistry</i> , 2006, 281, 11541-11552.	3.4	10
30	Integrated computational and <i>Drosophila</i> cancer model platform captures previously unappreciated chemicals perturbing a kinase network. <i>PLoS Computational Biology</i> , 2019, 15, e1006878.	3.2	10
31	Systems Pharmacology: An Overview. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2016, , 53-80.	0.6	7
32	Type II Binders Targeting the ðGLR-Out Conformation of the Pseudokinase STRAD. <i>Biochemistry</i> , 2021, 60, 289-302.	2.5	6
33	Correction to CSAR Benchmark Exercise of 2010: Selection of the Protein-Ligand Complexes. <i>Journal of Chemical Information and Modeling</i> , 2011, 51, 2146-2146.	5.4	4
34	DFGmodel: Predicting Protein Kinase Structures in Inactive States for Structure-Based Discovery of Type-II Inhibitors. <i>Biophysical Journal</i> , 2015, 108, 474a.	0.5	1